Phibro Animal Health Corp. (PAHC) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Phibro Animal Health Corp.

Soleno Therapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Arbutus Biopharma Corp.

Nurix Therapeutics, Inc.

MacroGenics, Inc.

Coherus BioSciences, Inc.

EyePoint Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

Erasca, Inc.

Why is Phibro Animal Health Corp. ?

With a growth in Net Profit of 2190.43%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 3 consecutive quarters
ROCE(HY) Highest at 17.8%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
PRE-TAX PROFIT(Q) Highest at USD 32.24 MM

With ROCE of 13.12%, it has a very attractive valuation with a 1.76 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 83.64%, its profits have risen by 183.5% ; the PEG ratio of the company is 0.1

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating performance in long term as well as near term

Along with generating 83.64% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Phibro Animal Health Corp. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Phibro Animal Health Corp. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Phibro Animal Health Corp.

75.28%

3.18

50.88%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.12%

EBIT Growth (5y)

10.55%

EBIT to Interest (avg)

4.29

Debt to EBITDA (avg)

3.40

Net Debt to Equity (avg)

2.50

Sales to Capital Employed (avg)

1.28

Tax Ratio

37.11%

Dividend Payout Ratio

805.37%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

12.74%

ROE (avg)

15.62%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.67

EV to EBIT

13.42

EV to EBITDA

9.97

EV to Capital Employed

1.76

EV to Sales

1.38

PEG Ratio

0.12

Dividend Yield

1.99%

ROCE (Latest)

13.12%

ROE (Latest)

17.19%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

32What is working for the Company

ROCE(HY)

Highest at 17.8%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

PRE-TAX PROFIT(Q)

Highest at USD 32.24 MM

NET PROFIT(Q)

Highest at USD 23.28 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 6.52 times

NET SALES(Q)

Highest at USD 378.7 MM

-4What is not working for the Company

DIVIDEND PAYOUT RATIO(Y)

Lowest at 28.36%

RAW MATERIAL COST(Y)

Grown by 10.66% (YoY

CASH AND EQV(HY)

Lowest at USD 147.39 MM

Here's what is working for Phibro Animal Health Corp.

Pre-Tax Profit

At USD 32.24 MM has Grown at 1,169.58%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 23.28 MM has Grown at 6,682.89%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Pre-Tax Profit

Highest at USD 32.24 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 23.28 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 378.7 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Net Sales

At USD 378.7 MM has Grown at 38.63%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 6.52 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Phibro Animal Health Corp.

Cash and Eqv

Lowest at USD 147.39 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Dividend Payout Ratio

Lowest at 28.36%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)

Raw Material Cost

Grown by 10.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales